Bioatla Inc BCAB:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 7:41 PM EDT
3.01quote price arrow up+0.01 (+0.33%)
Volume
5,666
Close
3.00quote price arrow up+0.39 (+14.94%)
Volume
1,271,596
52 week range
1.24 - 4.07
Loading...
  • Open2.88
  • Day High3.18
  • Day Low2.74
  • Prev Close2.61
  • 52 Week High4.07
  • 52 Week High Date05/15/23
  • 52 Week Low1.24
  • 52 Week Low Date10/27/23

Key Stats

  • Market Cap144.319M
  • Shares Out48.11M
  • 10 Day Average Volume1.07M
  • Dividend-
  • Dividend Yield-
  • Beta1.26
  • YTD % Change21.95

KEY STATS

  • Open2.88
  • Day High3.18
  • Day Low2.74
  • Prev Close2.61
  • 52 Week High4.07
  • 52 Week High Date05/15/23
  • 52 Week Low1.24
  • 52 Week Low Date10/27/23
  • Market Cap144.319M
  • Shares Out48.11M
  • 10 Day Average Volume1.07M
  • Dividend-
  • Dividend Yield-
  • Beta1.26
  • YTD % Change21.95

RATIOS/PROFITABILITY

  • EPS (TTM)-2.49
  • P/E (TTM)-1.21
  • Fwd P/E (NTM)-1.53
  • EBITDA (TTM)-128.466M
  • ROE (TTM)-98.37%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-40,382.00%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date07/30/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Bioatla Inc

 

Profile

MORE
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), BA3071, and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for...
Jay Short Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Richard Waldron
Chief Financial Officer, Senior Vice President
Christian Vasquez CPA
Chief Accounting Officer
Address
11085 Torreyana Road
San Diego, CA
92121
United States

Top Peers

SYMBOLLASTCHG%CHG
CRVS
Corvus Pharmaceuticals Inc
2.22-0.04-1.77%
PDSB
PDS Biotechnology Corp
3.50-0.04-0.99%
CTXR
Citius Pharmaceuticals Inc
0.6247-0.0629-9.1478%
ACET
Adicet Bio Inc
1.40+0.07+5.26%
CNTX
Context Therapeutics Inc
1.69-0.02-1.17%